Skip to content

Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.

Oct 2026 · Bioorganic chemistry (Print) · Vol 184, pp. 110676 · 0 citations · 48 references
Medicine

Abstract

Small-molecule modulators may complement antibody therapy, offering potential advantages such as optimizable chemical structures, improved tumor accessibility, and better flexibility in pharmacokinetic control. Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint receptor that suppresses T-cell function by interacting with MHC-II molecules; however, systematic research on small-molecule modulators targeting LAG-3 remains lacking. In this study, a multi-stage structure-guided screening process was employed to identify candidate compounds targeting a predicted binding pocket adjacent to the LAG-3/MHC-II interface. Starting with approximately 3.9 million compounds database, the study employed a sequential screening and prioritization process involving AutoDock-GPU docking, Glide hierarchical docking, physicochemical and ADMET screening, 500 ns molecular dynamics simulations, and MM/PBSA binding free energy analysis. Based on predicted binding conformations, interface stability, estimated binding energies, and drug-like properties, ligand160490 and ligand223516, hereafter termed Z21 and Z28, were ultimately prioritized for functional evaluation. In activated human peripheral blood mononuclear cells, Z28 increased the frequency of CD4+IFN-γ+ and CD8+IFN-γ+ T cells, whereas Z21 did not exhibit a similar effect. In the MC38 syngeneic tumor model, both Z21 and Z28, when used in combination with anti-PD-1, reduced tumor growth, accompanied by increased frequency of tumor-infiltrating CD8+ T cells. Together, the in vitro and in vivo results support Z21 and Z28 as prioritized small-molecule candidates for further investigations. Subsequent studies should focus on determining whether Z21 and Z28 exert their biological effects by directly binding to LAG-3 and interfering with LAG-3/MHC-II interaction. Our findings support further mechanistic and pharmacological evaluation of Z21 and Z28.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.